Open account
Sign up/Log in
Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
Sanofi reports Q1 Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance. Dupixent sales up 24.9% to €2,835B; on target to deliver €13B in 2024.
Seeking Alpha · 11h ago
Sanofi succeeds in late-stage trial for blood disorder candidate
Healthcare Sanofi succeeds in late-stage trial for blood disorder candidate. Sanofi's rilzabrutinib, an oral therapy for an autoimmune blood disorder called immune thrombocytopenia, reached the primary endpoint in a Phase 3 trial.
Seeking Alpha · 2d ago
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Healthcare GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma. A mid-stage trial indicated that the diabetes drug lixisenatide benefited patients with Parkinson's disease. The diabetes drug belongs to a popular class of obesity drugs called GLp-1 agonists.
Seeking Alpha · 04/12 16:02
Nurix gains after extending Sanofi research pact
Healthcare Nurix gains after extending Sanofi research pact. The companies joined hands in 2019 to develop drugs against a key therapeutic target called STAT6 in type 2 inflammation. Nurix Therapeutics can nominate a development candidate within a year. The company is on track to receive up to $2.5B in milestones and royalties.
Seeking Alpha · 04/09 18:15
CureVac posts early efficacy results for GSK-partnered flu shot
Healthcare CureVac posts early efficacy results for GSK-partnered flu shot. German biotech says its seasonal influenza vaccine candidate outperformed licensed products against influenza A strains in a mid-stage trial. The vaccine candidate developed with GSK underperformed against influenza B strains.
Seeking Alpha · 04/04 12:20
U.S. CDC warns bacteria causing meningitis are on the rise
Healthcare U.S. CDC warns bacteria causing meningitis are on the rise. 143 cases of invasive meningococcal disease reported this year, the highest annual number since 2014. Infected people aged 30–60 years, black or African American people, and HIV patients are most at risk.
Seeking Alpha · 03/30 14:50
FDA experts recommend changes to flu shots
Healthcare FDA experts recommend changes to flu shots for the 2024–2025 season. Group of independent advisers to the FDA voted unanimously to recommend changing the flu vaccines to reflect only the currently circulating viral strains. The move could potentially boost vaccine supplies. The group recommended against adding the vaccine component that targets the B/Yamagata lineage.
Seeking Alpha · 03/07 18:29
Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Apogee Therapeutics' APG777 shows promising Phase 1 results for atopic dermatitis. The antibody has a 75-day half-life, potentially reducing dosing frequency. Apogee is developing a novel antibody targeting IL-13 for the treatment of AD and asthma. The company reported Q4 earnings and pipeline updates today, inspiring a 30%-plus rally in its stock.
Seeking Alpha · 03/05 18:28
Webull offers Sanofi FR stock information, including NASDAQ: GCVRZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GCVRZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading GCVRZ stock methods without spending real money on the virtual paper trading platform.